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A Phosphorylcholine Polymer Platform for Cancer Drug Delivery 
PolyMPC is extremely hydrophilic and biocompatible:  Ishihara, Nakabayashi, Iwasaki, Armes, Lewis,.. 
PolyMPC:  current applications and future potential  
Longer lasting 
protein therapeutics 
Contact lenses 
Proclear (Copper Vision) 
     Stent devices 
Endeavor (Medtronic) 
Trimaxx and Dexamet (Abbott) 
BiodivYsio  (Biocompatibles) 
Current 
Future 
Why Polymers? Polymers Enhance Drug Delivery  
Prolonged Circulation; Enhanced Permeation and Retention 
Normal vessels have tight 
junctions between cells – 
allow minimal extravasation 
into healthy tissue  
Tumor vessels are 
disorganized and 
leaky 
Polymer/
drug flow 
through 
capillary 
pH ~ 7.4 
pH ~ 6.0 - 6.8 
Polymer-drug      
conjugates are large      
and are taken up into 
tumor tissue  
Passive targeting  
PolyMPC-CPT:  the first polyMPC pro-drug 
Drug loading:  18 wt %, 
CPT equivalent solubility: 36.7 mg/mL 
Bioconjugate Chemistry 2009; 
and Emrick, T.; Chen, X.J., McRae, S.  
WO/2010/068862   PCT/US2009/067665   
4-arm star PEGylation 
NKTR-102 
 PEGylated Irinotecan  (CPT11, Camptosar) 
Drug loading:  3.7 wt % 
CPT equivalent solubility: 6.7 mg/mL 
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Conjugate 8-A 
DOX release from polyMPC-DOX 
conjugates at pH 5.0 and 7.4 
PolyMPC-Doxorubicin pro-drugs 
pH 5.0 pH 7.4 
Bioconjugate Chemistry  2012 
Half-life of polyMPC-Dox samples range 
from 8-28 hours, depending on molecular 
weight and drug loading 
polyMPC-DOX 
Increasing wt percent Dox loading  
MeOH H2O 
PolyMPC-Dox soluble in water and  
injectable saline at very high DOX loading 
Labile  
bond  
In vitro and in vivo evaluation 
Pro- 
drug 
Pro- 
drug 
DOX 
Cell uptake  MCF7 24 h 
Bioconjugate Chemistry  2012 
Maximum tolerated dose 
(MTD) of polyMPC-Dox 
Nuclear uptake seen for polyMPC-Dox 
MTD values of 50 mg/kg or greater 
 
About 10 times that of Dox alone 
 
About twice that of Doxil 
In vivo experiments in mice:  4T1 breast cancer model 
Highly invasive and spontaneously metastatic tumor line 
Large tumor starting volume; 1 injection 
Survival   
Doxil:  40% at 7 days, 0% at 14 days 
polyMPC-Dox:  100% at 7 days 
             50% at 14 days  
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Free DOX 
Doxil 
pMPC-DOX 
Single injection 
Balb/c-4T1 efficacy: Tumor Volume
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Survival    
Day 15 with Dox:  10% survival 
Day 15 with polyMPC-Dox:  90% survival  
